Brought to you by 
Series C brings in $62.5mm for JenaValve Technology; adds $10mm then another $26.5mm
07 Aug 2015
Executive Summary
JenaValve Technology GMBH (markets the JenaValve transcatheter aortic valve implantation (TAVI) system) has raised $62.5mm through its Series C venture round. New investor GIMV and current shareholder Edmond de Rothschild Investment Partners co-led and were joined by new backers Legend Capital and Omega Funds as well as existing stakeholders Atlas Venture Fund, NeoMed Management, VI Partners, Sunstone Capital, plus five other undisclosed investors. The funds will be used for clinical trials of its JenaValve transfemoral device in Europe and the US; to expand its commercial infrastructure; and to gain regulatory approval in China. The company anticipates an EU launch in 2014. Its JenaValve transapical TAVI system has been available in Europe since 2011.
Deal Industry
- Medical Devices
-
Medical Devices
- Implantable Devices
-
Surgical Equipment & Devices
- Minimally or Less Invasive
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Series C brings in $62.5mm for JenaValve Technology; adds $10mm then another $26.5mm
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice